Detalhe da pesquisa
1.
Association between CD8 and PD-L1 expression and outcomes after radical prostatectomy for localized prostate cancer.
Prostate
; 81(1): 50-57, 2021 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32986884
2.
Patients with Biopsy Gleason 9 and 10 Prostate Cancer Have Significantly Worse Outcomes Compared to Patients with Gleason 8 Disease.
J Urol
; 194(1): 91-7, 2015 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-25623747
3.
Elevated insulin-like growth factor binding protein-1 (IGFBP-1) in men with metastatic prostate cancer starting androgen deprivation therapy (ADT) is associated with shorter time to castration resistance and overall survival.
Prostate
; 74(3): 225-34, 2014 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-24132762
4.
Elevated IL-8, TNF-α, and MCP-1 in men with metastatic prostate cancer starting androgen-deprivation therapy (ADT) are associated with shorter time to castration-resistance and overall survival.
Prostate
; 74(8): 820-8, 2014 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-24668612
5.
Bone targeted therapy and skeletal related events in the era of enzalutamide and abiraterone acetate for castration resistant prostate cancer with bone metastases.
Prostate Cancer Prostatic Dis
; 24(2): 341-348, 2021 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-32884090
6.
Compound Genomic Alterations of TP53, PTEN, and RB1 Tumor Suppressors in Localized and Metastatic Prostate Cancer.
Eur Urol
; 76(1): 89-97, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-30553611
7.
Impact of new systemic therapies on overall survival of patients with metastatic castration-resistant prostate cancer in a hospital-based registry.
Prostate Cancer Prostatic Dis
; 22(3): 420-427, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-30643173
8.
Clinical Outcomes of First-line Abiraterone Acetate or Enzalutamide for Metastatic Castration-resistant Prostate Cancer After Androgen Deprivation Therapy + Docetaxel or ADT Alone for Metastatic Hormone-sensitive Prostate Cancer.
Clin Genitourin Cancer
; 16(2): 130-134, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29331381
9.
Development of an integrated prostate cancer research information system.
Clin Genitourin Cancer
; 5(1): 61-6, 2006 Jun.
Artigo
em Inglês
| MEDLINE | ID: mdl-16859581
10.
Duration of Androgen Deprivation Therapy for High-Risk Prostate Cancer: Application of Randomized Trial Data in a Tertiary Referral Cancer Center.
Clin Genitourin Cancer
; 14(4): e299-305, 2016 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-26778006
11.
Role of androgen deprivation therapy in early salvage radiation among patients with prostate-specific antigen level of 0.5 or less.
Clin Genitourin Cancer
; 13(1): e1-6, 2015 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-25103271
12.
Association of prostate cancer risk Loci with disease aggressiveness and prostate cancer-specific mortality.
Cancer Prev Res (Phila)
; 4(5): 719-28, 2011 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-21367958
13.
The risk of renal impairment in hormone-refractory prostate cancer patients with bone metastases treated with zoledronic acid.
Cancer
; 109(6): 1090-6, 2007 Mar 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-17311345